{"url":"https://newsforagent.com/news/2026-11-14/prolynx-obesityweek-amylin-quarterly-dosing","markdown_url":"https://newsforagent.com/news/2026-11-14/prolynx-obesityweek-amylin-quarterly-dosing.md","title":"ProLynx Shows 12-Week Weight Loss With Single Dose","headline":"ProLynx Reports 12-Week Weight Loss in Rats From One Amylin Agonist Dose at ObesityWeek 2026","description":"ProLynx presented preclinical data showing a single amylin agonist dose sustained weight loss for 12 weeks in rats, supporting once-quarterly dosing.","section":"Research & Clinical Trials","published_at":"2026-11-14T17:59:33+00:00","modified_at":"2026-11-14T17:59:33+00:00","author":"News Desk","key_takeaways":["ProLynx reported sustained weight loss for 12 weeks in diet-induced obese rats after a single dose of an amylin agonist.","The company's hydrogel microsphere platform sets peptide half-life through linker chemistry rather than fatty-acid lipidation.","ProLynx closed a $70 million Series A in December 2025 co-led by 5AM Ventures, OrbiMed and Monograph Capital."],"companies":[{"name":"ProLynx","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003au9/prolynx","website":"https://prolynxinc.com"}],"source":{"publisher":"FinancialContent Business Page","title":"Prolynx Presents Preclinical Data at ObesityWeek® 2026 Supporting the Potential for Quarterly Dosing of Ultra-Long-Acting Anti-Obesity Peptides","url":"https://www.financialcontent.com/article/gnwcq-2026-11-14-prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides"},"other_sources":[],"tags":["Research & Clinical Trials","ProLynx"],"body_markdown":"ProLynx reported on November 14, 2026 that a single dose of an amylin agonist sustained weight loss for 12 weeks in rats with diet-induced obesity, data presented at ObesityWeek 2026 in three posters. The Emeryville, California-based biotechnology company announced the findings in a release carried by the [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-14-prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides).\n\n## How ProLynx's Hydrogel Platform Works\n\n[ProLynx](https://akta.pro/company-profiles/0003au9/prolynx) develops ultra-long-acting medicines for obesity and related metabolic diseases. Its platform tethers peptides to biodegradable hydrogel microspheres through releasable linkers that cleave at a preprogrammed rate, so half-life is governed by release from the depot rather than by the peptide alone.\n\nMost long-acting obesity peptides rely on fatty-acid lipidation, which binds the drug to albumin and generally limits practical half-life to about one week, according to the release. ProLynx said its approach can extend exposure over several months, keep peak concentrations low and preserve weight-loss efficacy comparable to lipidated peptides.\n\nThe three posters covered an amylin agonist that sustained 12-week weight loss in diet-induced obese rats after a single dose, a GLP-1/GIP dual agonist that reached a half-life greater than one month without lipidation, and native peptides that delivered the same maximal weight loss as their lipidated counterparts. All three were presented on November 14, 2026, from 7:30 to 8:30 p.m. ET and are available on the [ProLynx website](https://prolynxinc.com).\n\n\"Today's obesity medicines have transformed care, but weekly injections and dosing-related side effects remain real barriers to long-term treatment,\" said Chris Boulton, Chief Executive Officer of ProLynx. \"These three presentations show what our platform can do across incretin and amylin biology.\"\n\n## ProLynx's Funding and Pipeline Records\n\nProLynx closed a $70 million Series A in December 2025 co-led by 5AM Ventures, OrbiMed and Monograph Capital, with all three partners joining the board, according to akta.pro [company records](https://akta.pro/company-data). The same records show the company advanced PLX-821, an ultra-long-acting semaglutide, as its lead program targeting once-monthly and once-quarterly dosing for obesity and type 2 diabetes, alongside a pipeline of dual and triple agonists, amylin-based therapies and combination approaches. ProLynx is in preclinical development, advancing toward IND enablement and clinical proof-of-concept.\n\n## ProLynx's Leadership Appointments\n\nProLynx appointed Simon Harnest as Chief Financial Officer and Amer Mirza as Chief Scientific Officer to its leadership team, Investing.com reported in July 2026. Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, placed Mirza as Chief Scientific Officer, Aijourn reported on July 16, 2026.\n\n## What ProLynx Said About Translation\n\n\"The overall efficacy of an anti-obesity peptide reflects the interplay between its intrinsic potency and its sustained, steady-state exposure,\" said Amer Mirza, PhD, Chief Scientific Officer of ProLynx. \"Our platform uncouples the two, delivering tunable half-life extension without relying on a lipid tail.\"\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}